Healthy volunteers needed to compare two survodutide formulas
NCT ID NCT07221591
First seen Nov 01, 2025
Summary
This study tests a new formulation of survodutide, a medicine being developed for obesity and liver conditions. About 100 healthy adults aged 18-65 with a BMI between 27 and 40 will receive weekly injections of either the current or new formula for 28 weeks. Researchers will measure how much drug gets into the blood and monitor for side effects. This is a phase 1 trial, so it focuses on drug absorption and safety, not treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CRS Clinical Research Services Berlin GmbH
Berlin, 13627, Germany
-
CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.